The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:1048-1050 September 6, 2007 Number 10
NextNext

Smoldering Multiple Myeloma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Kyle, R. A.
-PubMed Citation
To the Editor: Kyle et al. (June 21 issue)1 propose a clinically useful risk-stratification model of progression from smoldering multiple myeloma to overt multiple myeloma. Gene-expression–signature data might enhance their model.

Recent studies have shown that a 50-gene panel can distinguish monoclonal gammopathy of undetermined significance (MGUS)–like multiple myeloma (better prognosis) from non–MGUS-like multiple myeloma.2 Studies have also shown that multiple myeloma can be divided into eight distinct molecular subtypes with different prognoses.3 Smoldering multiple myeloma with gains of chromosome 1q21 is associated with an increased risk of conversion to multiple myeloma,4 and a gene-expression signature of high-risk disease, reflecting . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.